Market Research Industry Reports

NASH [2017]: Bulletin #1


Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the recent positive recommendation by a data safety monitoring board (DSMB) for the continuation of the RESOLVE-IT Phase III trial with Genfit Pharmaceuticals elafibranor without any modifications. KOLs discuss the positive Phase II data presented at the international EASL congress 2017 for two novel fibroblast growth factor (FGF) modulators, Bristol-Myers Squibbs BMS-986036 and NGM Biopharmaceuticals NGM282. Experts also cover late-breaking data presented at EASL 2017 for Gileads GS-0976, an oral inhibitor of acetyl-CoA carboxylase (ACC), in patients with NASH.

Business Questions:

How do KOLs view the positive recommendation issued by the DSMB for continuation of the RESOLVE-IT trial with elafibranor?
Are KOLs satisfied with elafibranors safety profile in NASH?
What are the likely reasons behind the delay in recruitment of NASH patients with F2/F3 fibrosis in the RESOLVE-IT study?
Are KOLs concerned about the delay in patient recruitment for RESOLVE-IT and other clinical studies in NASH?
What are KOL opinions on the improvement in fat reduction reported for both BMS-986036 and NGM282 compounds at EASL 2017?
Will the improvements in hepatic fat content with FGF therapies correlate with long-term clinical outcomes?
How do KOLs view the surrogate endpoint of MRI-PDFF adopted in early-stage studies and can it compete with the gold-standard biopsy?
Do KOLs hold any safety concerns with FGF modulation in NASH?
What sort of role do experts envisage for FGF therapies in the NASH treatment space, or is it too early to tell?
How do KOLs view the data reported for Gileads GS-0976 at EASL 2017, and are they hopeful about the therapy in NASH?
Are the experts optimistic about GS-0976 combined with the MAP kinase inhibitor selonsertib?
If approved, what type of NASH patients would GS-0976 be best positioned in?

Global Non-Alcoholic Steatohepatitis (NASH) Market Research Report 2018

Non-Alcoholic Steatohepatitis (NASH) Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on

USD 2850View Report

Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]

Are novel therapies set to revolutionise NASHNo drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but this could all change in the next 3-5 years. Four late-stage

USD 8495View Report

RCC [2017]: Bulletin #2

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; the early halting of the CheckMate-214 trial and subsequent

USD 1095View Report

RCC [2017]: Bulletin #1

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; data released from Bristol-Myers Squibbs Phase III CheckMate-214 study,

USD 1045View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE


We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube